Principal Financial Group Inc. Sells 63,317 Shares of Charles River Laboratories International, Inc. $CRL

Principal Financial Group Inc. cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 53.0% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 56,182 shares of the medical research company’s stock after selling 63,317 shares during the period. Principal Financial Group Inc.’s holdings in Charles River Laboratories International were worth $9,691,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Tema Etfs LLC bought a new stake in Charles River Laboratories International in the 4th quarter valued at about $26,000. Los Angeles Capital Management LLC acquired a new position in shares of Charles River Laboratories International during the 4th quarter worth approximately $42,000. Sfam LLC bought a new position in shares of Charles River Laboratories International during the fourth quarter worth approximately $43,000. Activest Wealth Management increased its holdings in shares of Charles River Laboratories International by 10,900.0% during the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after purchasing an additional 218 shares during the period. Finally, Geneos Wealth Management Inc. raised its position in shares of Charles River Laboratories International by 98.0% in the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after buying an additional 145 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Down 1.3%

CRL stock opened at $226.38 on Friday. The firm has a 50-day moving average price of $198.80 and a 200-day moving average price of $187.51. Charles River Laboratories International, Inc. has a 12 month low of $144.26 and a 12 month high of $238.85. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90. The stock has a market capitalization of $10.90 billion, a P/E ratio of -60.21, a price-to-earnings-growth ratio of 2.52 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.10. The company had revenue of $995.83 million for the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The firm’s revenue was up 1.2% on a year-over-year basis. During the same period in the previous year, the firm posted $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 11.05 EPS for the current fiscal year.

Insiders Place Their Bets

In other Charles River Laboratories International news, Director James C. Foster sold 75,000 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $225.00, for a total value of $16,875,000.00. Following the sale, the director owned 31,596 shares in the company, valued at $7,109,100. This trade represents a 70.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Sanford C. Bernstein set a $250.00 price target on Charles River Laboratories International in a research note on Wednesday, July 1st. BNP Paribas Exane set a $250.00 price objective on Charles River Laboratories International in a report on Wednesday, July 1st. Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Royal Bank Of Canada initiated coverage on Charles River Laboratories International in a report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 target price on the stock. Finally, Mizuho raised their price target on Charles River Laboratories International from $192.00 to $230.00 and gave the stock a “neutral” rating in a research report on Monday, July 13th. Eleven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $220.75.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.